Commentary: British biotech industry lagging

09/14/2004 | Guardian (London), The

Heather Tomlinson of The Guardian writes that her country's slow growth in the biotechnology sector is partly the result of U.S. firms reaping most of the financial gains from highly effective drugs for rheumatoid arthritis, such as Remicade, Enbrel and Humira, all developed by British scientists. She says the U.K. biotechnology industry lags behind because, unlike its American counterparts, it fails to make its research findings commercially viable, and many companies are unwilling to take the financial risk necessary to bring new therapies to the market.

View Full Article in:

Guardian (London), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations